compounding drugs


The first FDA-cleared syringe
for intravitreal use.

Pine Pharmaceuticals is proud to introduce StaClear®. The first FDA-cleared syringe for intravitreal use. Designed to provide additional peace of mind to patients and providers alike, we are excited to offer this groundbreaking syringe option for repackaged bevacizumab* exclusively to our customers.

Contact us

The StaClear® Story

A better syringe – built for retina specialists.

TriboFilm Research developed the StaClear® syringe with the physician in mind. Easy-to-read barrel markings, zero dead space design, attached 31-gauge – 5/16″ needle, and more make this syringe stand out. Oh, and did we mention it’s FDA-cleared for intravitreal use?

Learn more

Available exclusively to our customers.

Our customers get first access to this groundbreaking syringe option for repackaged bevacizumab*. Connect with your Pine representative or our friendly Customer Support team today to learn how you can integrate StaClear® into your practice.

Contact us

Supporting retina and ophthalmology practices since 2007.

Pine began supporting ophthalmologists and retina specialists in 2007 through our Buffalo-based 503A sister pharmacy. Today, Pine Pharmaceuticals provides an extensive selection of sterile compounded and repackaged drug products to healthcare professionals and facilities nationwide.

Our products

*Bevacizumab is not FDA-approved for intravitreal use. StaClear® is the first fillable syringe FDA-cleared for intravitreal use. StaClear® is a registered trademark of TriboFilm Research, Inc. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.